The 21-gene Oncotype DX Breast Recurrence Score may inform decisions on adjuvant chemotherapy in postmenopausal luminal ERBB2-negative breast cancer with 1 to 3 metastatic ALNs without CALND. Here, ERBB2 is linked to breast carcinoma.